Over the next few days I will share my experience at #ASCO24 , the science I learned , amazing people I spoke to and of course my presentation on social media.
Late in the day on Friday, I finally got to McCormick Place. The traffic from the airport was dreadful but I arrived in time to pick up my badge from the Faculty Lounge. Then I headed to my favorite sushi place - Nui Sushi for dinner.
Rapid Oral Abstract Session Highlights. (I missed some sessions as I had scheduled a time to practice my presentation. )
Ovarian Cancer: AXL expression can be used as a biomarker in OC. Those with high AXL expression had improved PFS and OS when treated with Bateraxcept in combo with taxol.
Rapid Oral abstracts #gyncsm #ASCO24
— Dee Sparacio (@womenofteal) June 1, 2024
AXLerate-OC GOG 3059 Ph 3 , Dr Fuh batiraxcept AVB -S6-500 w/ paclitaxel in plat recurrent OC AXL expressed in OC. pic.twitter.com/FR8cqbaRYC
Ovarian Cancer: Use of suvemcitug, an anti-VEGF drug with chemo, met PFS goal 5.49 months vs placebo at 2.73 months.
Rapid oral abstract #gyncsm #ASCO24 Ph 3 suvemcitug anti-VEGF with chemo, common AE’s met primary end pt pic.twitter.com/mpvDwNAofO
— Dee Sparacio (@womenofteal) June 1, 2024
Ovarian , Fallopian, Peritoneal Cancers: Oral cyclophosphamide can be used together- Objective response rate 40%
#gyncsm #ASCO24 Dr Eyada oral cyclophosphamide and Bev in recurrent OC , fallopian tube or peritoneal , retro study pic.twitter.com/MEOzbRgCUv
— Dee Sparacio (@womenofteal) June 1, 2024
President's Speech and Invited Speakers
Dr Lynn Schuchter,President of ASCO, inspiring speech.
We will continue to fight cancer all over the world! ASCO president DR Schucter YES! #ASCO24 #gyncsm pic.twitter.com/uIp3kgY7tg
— Dee Sparacio (@womenofteal) June 1, 2024
Jonathan Carlson, Microsoft Health Futures, spoke on AI use in medicine
#ASCO24 Jonathan Carlson speaking about General AI in Medicine #gyncsm pic.twitter.com/RkAxWriruA
— Dee Sparacio (@womenofteal) June 1, 2024
Challenges are ecosystem challenges .
— Dee Sparacio (@womenofteal) June 1, 2024
AI can demystify medicine for patients .
Adopt AI for oncology radiology images Carlson #ASCO24 #gyncsm pic.twitter.com/6KiWJ1VETM
Abraham Verghese , Stanford spoke next relating to the meeting theme Art and Science
“Covenant of Water” Author and physician sharing stories highlighting Curing vs healing. A Med exam can be transforming - it can seal a patient- physician relationship.
— Dee Sparacio (@womenofteal) June 1, 2024
Listen to the patient story! #ASCO24 #gyncsm pic.twitter.com/pgC7GS8L57
Dr Rathmell , NCI Director
— Dee Sparacio (@womenofteal) June 1, 2024
Make trials more accessible. #ASCO24 #gyncsm pic.twitter.com/nNxXZXorFh
Clinical Science Symposium Novel combinations across the gyn cancer spectrum
Ovarian Cancer combinations:
#gyncsm #ASCO24
— Dee Sparacio (@womenofteal) June 1, 2024
Novel combos for gyn cancers Dr Matulonis
There are successful combos.
ATR inhibitors +PARP , being tested ; olaparib and PI3K as did not see superiority pic.twitter.com/f6LtzNgV91
Cervical Cancer mTOR inhibitors
#ASCO24 #gyncsm Dr Li
— Dee Sparacio (@womenofteal) June 1, 2024
mTOR inhibitor Onatasertib &toripalimab - checkpoint inhibitor in cervical cancer pic.twitter.com/ixSqT9D4Yc
Ovarian Cancer - overcoming PARP resistance , HRD status did not impact response
#ASCO24 #gyncsm Dr Simpkin CAPRI study ATRi and PARPi combo to overcome PARP resistance in HGSOC strong preclinical synergy, cohort A results ORR at 49%, AE’s anemia , nausea , fatigue - Dose reduced in 40% of patients
— Dee Sparacio (@womenofteal) June 1, 2024
Combo exhibited response irrespective of HRD stat pic.twitter.com/AVj2VrdJTM
A review of combos:
#ASCO24 #gyncsm review of combos vs std of care by Dr Banerjee pic.twitter.com/NLVHdoig3L
— Dee Sparacio (@womenofteal) June 1, 2024
Endometrial cancers CTK4 inhibitors
#ASCO24 #UCAM #gyncsm
— Dee Sparacio (@womenofteal) June 1, 2024
Dr Green endometrial ca incidence rising 1% a yr. CDK4 elevated in Endo ca, study abemacilib + fulvestrant ORR 44% , PFS 9.0 months , AEs neutropenia, anemia, diarrhea , responses in endometriod , copy # low had durable responses pic.twitter.com/W2eFSV4I1v
Future Endometrial Cancer work
Dr Cobb review of endometrial cancers future work (borrowing from BC) in subgroups of Endometrial cancers - CDK 4/6 etc pic.twitter.com/SYvTnPRyqE
— Dee Sparacio (@womenofteal) June 1, 2024
I finished the day participating in a panel with Dr Gil Morgan and Dr Gil Lopez on Harnessing the Power of Social Media. What an honor! Below are a few tweets from the audience. Dr Morgan spoke on using social media to improve global oncology and the The OncoAlert Consortium. Dr Lopez spoke on using social media to advance research and professional development. I spoke on social media to educate patients with cancer and clinicians.
Dee Sparacio @womenofteal flanked by the two Gils (Gil-squared) presents #patientadvocacy as a #ovca survivor using #SoMe to unite other patients and engage clinicians to improve awareness, advocacy and positively improve outcomes. #ASCO24 @stage4kelly pic.twitter.com/7moR2nwUHn
— Dr Joseph McCollom DO (@realbowtiedoc) June 1, 2024
Rockstar #gyncsm advocate (and @AdvocateCollab member) @womenofteal taking the stage after "Gil squared" presos (@weoncologists and @GlopesMd) to share how patients & advocates use social media: education, support, advocacy, and interaction with clinicians/researchers #ASCO24 pic.twitter.com/N8vIL1gTNS
— Stacey Tinianov (she/her) MPH, BCPA (@coffeemommy) June 1, 2024
@womenofteal discussing the birth of #gynCSM and important work and research at #ASCO24
— Annie Ellis (@Stigetta) June 1, 2024
Trying this again with correct hashtag! pic.twitter.com/v8tTFqLDYn
Check back to read posts highlighting Sunday's Session and the connections I made at ASCO with researchers, clinicians and other advocates.
Dee
Every Day is a Blessing!
No comments:
Post a Comment